Protocol Ledger

NCT06561607 · Phase III · ACTIVE NOT RECRUITING

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT06561607 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-11 Enrollment: 542 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06561607
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)542 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06561607
Protocol FieldVerified Registry Value
NCT IdentifierNCT06561607
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment542 participants (ESTIMATED)
Registered Start Date2024-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI